Xinxiang Tuoxin Pharmaceutical Co.Ltd. Market Cap ($384.05 Million)
Market Cap & Net Worth: Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)
Xinxiang Tuoxin Pharmaceutical Co.Ltd. market cap. Xinxiang Tuoxin Pharmaceutical Co.Ltd. (SHE:301089) has a market capitalization of $384.05 Million (CN¥2.62 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #13320 globally and #3914 in its home market, demonstrating a -0.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s stock price CN¥20.74 by its total outstanding shares 126544500 (126.54 Million). Also see cash flow conversion of Xinxiang Tuoxin Pharmaceutical Co.Ltd. for how efficiently the company converts equity into cash flow.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Market Cap History (2021–2026)
Xinxiang Tuoxin Pharmaceutical Co.Ltd. market cap history from 2021 to 2026. Data shows change from $1.47 Billion to $384.05 Million (-6.10% CAGR). Check Xinxiang Tuoxin Pharmaceutical Co.Ltd. share price for real-time trading data and today's change.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Xinxiang Tuoxin Pharmaceutical Co.Ltd. growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.37x
Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s market cap is 1.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.47 Billion | $502.48 Million | $65.71 Million | 2.93x | 22.37x |
| 2022 | $1.32 Billion | $784.72 Million | $286.54 Million | 1.68x | 4.60x |
| 2023 | $993.65 Million | $835.51 Million | $243.07 Million | 1.19x | 4.09x |
| 2024 | $522.01 Million | $421.69 Million | -$19.88 Million | 1.24x | N/A |
| 2025 | $518.49 Million | $378.34 Million | -$69.66 Million | 1.37x | N/A |
Competitor Companies of 301089 by Market Capitalization
Companies near Xinxiang Tuoxin Pharmaceutical Co.Ltd. in the global market cap rankings as of November 5, 2026. Also see how large is Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s balance sheet for a full breakdown of the balance sheet.
Key companies related to Xinxiang Tuoxin Pharmaceutical Co.Ltd. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Xinxiang Tuoxin Pharmaceutical Co.Ltd. (2021–2026)
Market capitalization of Xinxiang Tuoxin Pharmaceutical Co.Ltd. from 2021 to today. Between 2021 and today, Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s market cap moved from $1.47 Billion to $ 384.05 Million, with a yearly change of -6.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥384.05 Million | -25.93% |
| 2025 | CN¥518.49 Million | -0.67% |
| 2024 | CN¥522.01 Million | -47.47% |
| 2023 | CN¥993.65 Million | -24.59% |
| 2022 | CN¥1.32 Billion | -10.38% |
| 2021 | CN¥1.47 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Xinxiang Tuoxin Pharmaceutical Co.Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $384.05 Million USD |
| MoneyControl | $384.05 Million USD |
| MarketWatch | $384.05 Million USD |
| marketcap.company | $384.05 Million USD |
| Reuters | $384.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xinxiang Tuoxin Pharmaceutical Co.Ltd.
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, cytosine, 5-fluorocytosine, cytidine, uridine; an… Read more